Phosphotyrosine signaling analysis in human tumors is confounded by systemic ischemia-driven artifacts and intra-specimen heterogeneity
about
Recent findings and technological advances in phosphoproteomics for cells and tissuesRecent progress in protein profiling of clinical tissues for next-generation molecular diagnostics.Quantitative Profiling of Protein Tyrosine Kinases in Human Cancer Cell Lines by Multiplexed Parallel Reaction Monitoring AssaysReproducibility of Differential Proteomic Technologies in CPTAC Fractionated XenograftsType 1 diabetes cadaveric human pancreata exhibit a unique exocrine tissue proteomic profileEffective implementation of novel MET pharmacodynamic assays in translational studies.Proteomics insights into DNA damage response and translating this knowledge to clinical strategies.Profiling the effects of short time-course cold ischemia on tumor protein phosphorylation using a Bayesian approach.Common errors in mass spectrometry-based analysis of post-translational modifications.Phosphoproteomics in translational research: a sarcoma perspective.Cell signaling regulation by protein phosphorylation: a multivariate, heterogeneous, and context-dependent process.Advances in mass spectrometry based strategies to study receptor tyrosine kinases.Assays for Qualification and Quality Stratification of Clinical Biospecimens Used in Research: A Technical Report from the ISBER Biospecimen Science Working Group.P-MartCancer-Interactive Online Software to Enable Analysis of Shotgun Cancer Proteomic Datasets.Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance.Quantitative Analysis of Tyrosine Kinase Signaling Across Differentially Embedded Human Glioblastoma Tumors.
P2860
Q26781752-55522191-3938-4DCD-BC5D-9E091BB6F59AQ35714211-784FCBAF-32F8-4C31-8BDD-22914D42DE6DQ35859573-EF21DD96-14EE-4448-9662-0C2C85ACCD4BQ36654799-2BEB5F93-5536-4DF5-B63E-AA7053532436Q36970856-06988AEB-9D28-4C04-B0C6-5C59F3A4F511Q37597853-B4A54E18-3347-4993-A5AD-1CDEF4212ED2Q37676851-5BF00095-895A-4AEB-AA73-A416AF6F99FEQ38662464-E9A230E7-8773-420D-A310-E8AB4DE10631Q38669393-56A46905-F481-43ED-BA56-9363B0B4C482Q38708614-CB914FF3-DDAD-412D-A88C-523375A21D93Q38890784-92D951AD-4840-4C6C-80FA-20AFF9BB9DB7Q38934587-E2E35740-4992-4DA8-818B-561B3369401DQ46192276-A507E154-3290-4A39-B846-5B5B1672BE58Q47577234-ABF2B420-4E34-4CCC-A218-F2A8F016EE37Q47767201-0217CE94-ABCD-44E1-9F35-37CA690E520AQ47854601-1C1DBE3F-DFFC-4005-9686-3A6081C81E4B
P2860
Phosphotyrosine signaling analysis in human tumors is confounded by systemic ischemia-driven artifacts and intra-specimen heterogeneity
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Phosphotyrosine signaling anal ...... d intra-specimen heterogeneity
@ast
Phosphotyrosine signaling anal ...... d intra-specimen heterogeneity
@en
type
label
Phosphotyrosine signaling anal ...... d intra-specimen heterogeneity
@ast
Phosphotyrosine signaling anal ...... d intra-specimen heterogeneity
@en
prefLabel
Phosphotyrosine signaling anal ...... d intra-specimen heterogeneity
@ast
Phosphotyrosine signaling anal ...... d intra-specimen heterogeneity
@en
P2093
P2860
P1433
P1476
Phosphotyrosine signaling anal ...... d intra-specimen heterogeneity
@en
P2093
Aaron S Gajadhar
Alan J Herline
Clinical Proteomic Tumor Analysis Consortium
Douglas A Levine
Hannah Johnson
Kent Shaddox
Kerry Wiles
Mary Kay Washington
Robbert J C Slebos
P2860
P304
P356
10.1158/0008-5472.CAN-14-2309
P407
P577
2015-02-10T00:00:00Z